Axalimogene filolisbac: Additional Phase II data

Data from 24 evaluable patients with persistent or recurrent metastatic cervical cancer in stage 2 of the 2-stage, open-label, U.S. Phase II GOG/NRG-0265 trial

Read the full 241 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE